Jessica Oh1, Elizabeth Garabedian2, Ramsay Fuleihan3, Charlotte Cunningham-Rundles4. 1. Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: jess.oh.md@gmail.com. 2. National Human Genome Research Institute (NHGRI), National Institutes of Health, Bethesda, Md. 3. Division of Pediatric Allergy, Immunology, and Rheumatology, Columbia University Irving Medical Center, New York, NY. 4. Division of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
BACKGROUND: Activated phosphoinositide 3-kinase δ syndrome is a combined primary immunodeficiency characterized by gain-of-function mutations in PIK3CD and PIK3R1. Activated phosphoinositide 3-kinase δ syndrome demonstrates a large range of phenotypes including respiratory and herpesvirus infections, lymphadenopathy, autoimmunity, and developmental delay. OBJECTIVE: To describe clinical phenotypes and disease outcomes of a large activated phosphoinositide 3-kinase δ syndrome cohort from the United States Immunodeficiency Network Registry. METHODS: A total of 38 patients were enrolled in the United States Immunodeficiency Network Registry, and 2 additional patients were obtained from the Clinical Immunology Division at Mount Sinai Hospital. Each patient's demographic characteristics, disease complications, genetic studies, laboratory data, therapeutic interventions, and clinical outcomes were reviewed. RESULTS: There was a high frequency of respiratory infections (70.0% pneumonia) and herpesvirus infections (37.5%). Bronchiectasis was observed in 45.0% of patients. Lymphadenopathy was common (52.5%), and 12.5% of patients developed lymphoma. Neurological and developmental findings were common: 20.0% had developmental delay, 15.0% had seizures, and 10.0% had dysmorphic features. Asthma was more common in PIK3CD compared with PIK3R1 patients (63.6% vs 14.3%). More subjects with PIK3CD had CD3 lymphopenia compared with the PIK3R1 cohort. Seven patients underwent hematopoietic stem cell transplantation. One patient died from infectious complications. CONCLUSIONS: This is the first cohort comparing clinical manifestations in PIK3CD and PIK3R1 patients from the USIDNET Registry. Similar frequencies of respiratory and herpesvirus infections, lymphadenopathy, and developmental delay were observed compared with previous cohort studies. However, a higher frequency of asthma and CD3 lymphopenia in the PIK3CD cohort compared with the PIK3R1 cohort was observed.
BACKGROUND: Activated phosphoinositide 3-kinase δ syndrome is a combined primary immunodeficiency characterized by gain-of-function mutations in PIK3CD and PIK3R1. Activated phosphoinositide 3-kinase δ syndrome demonstrates a large range of phenotypes including respiratory and herpesvirus infections, lymphadenopathy, autoimmunity, and developmental delay. OBJECTIVE: To describe clinical phenotypes and disease outcomes of a large activated phosphoinositide 3-kinase δ syndrome cohort from the United States Immunodeficiency Network Registry. METHODS: A total of 38 patients were enrolled in the United States Immunodeficiency Network Registry, and 2 additional patients were obtained from the Clinical Immunology Division at Mount Sinai Hospital. Each patient's demographic characteristics, disease complications, genetic studies, laboratory data, therapeutic interventions, and clinical outcomes were reviewed. RESULTS: There was a high frequency of respiratory infections (70.0% pneumonia) and herpesvirus infections (37.5%). Bronchiectasis was observed in 45.0% of patients. Lymphadenopathy was common (52.5%), and 12.5% of patients developed lymphoma. Neurological and developmental findings were common: 20.0% had developmental delay, 15.0% had seizures, and 10.0% had dysmorphic features. Asthma was more common in PIK3CD compared with PIK3R1 patients (63.6% vs 14.3%). More subjects with PIK3CD had CD3 lymphopenia compared with the PIK3R1 cohort. Seven patients underwent hematopoietic stem cell transplantation. One patient died from infectious complications. CONCLUSIONS: This is the first cohort comparing clinical manifestations in PIK3CD and PIK3R1 patients from the USIDNET Registry. Similar frequencies of respiratory and herpesvirus infections, lymphadenopathy, and developmental delay were observed compared with previous cohort studies. However, a higher frequency of asthma and CD3 lymphopenia in the PIK3CD cohort compared with the PIK3R1 cohort was observed.
Authors: Marjolein Wentink; Virgil Dalm; Arjan C Lankester; Pauline A van Schouwenburg; Liesbeth Schölvinck; Tomas Kalina; Radana Zachova; Anna Sediva; Annechien Lambeck; Ingrid Pico-Knijnenburg; Jacques J M van Dongen; Malgorzata Pac; Ewa Bernatowska; Martin van Hagen; Gertjan Driessen; Mirjam van der Burg Journal: Clin Immunol Date: 2017-01-17 Impact factor: 3.969
Authors: Gillian L Dornan; Braden D Siempelkamp; Meredith L Jenkins; Oscar Vadas; Carrie L Lucas; John E Burke Journal: Proc Natl Acad Sci U S A Date: 2017-02-06 Impact factor: 11.205
Authors: Carrie L Lucas; Hye Sun Kuehn; Fang Zhao; Julie E Niemela; Elissa K Deenick; Umaimainthan Palendira; Danielle T Avery; Leen Moens; Jennifer L Cannons; Matthew Biancalana; Jennifer Stoddard; Weiming Ouyang; David M Frucht; V Koneti Rao; T Prescott Atkinson; Anahita Agharahimi; Ashleigh A Hussey; Les R Folio; Kenneth N Olivier; Thomas A Fleisher; Stefania Pittaluga; Steven M Holland; Jeffrey I Cohen; Joao B Oliveira; Stuart G Tangye; Pamela L Schwartzberg; Michael J Lenardo; Gulbu Uzel Journal: Nat Immunol Date: 2013-10-28 Impact factor: 25.606
Authors: Maria Elena Maccari; Hassan Abolhassani; Asghar Aghamohammadi; Alessandro Aiuti; Olga Aleinikova; Catherine Bangs; Safa Baris; Federica Barzaghi; Helen Baxendale; Matthew Buckland; Siobhan O Burns; Caterina Cancrini; Andrew Cant; Pascal Cathébras; Marina Cavazzana; Anita Chandra; Francesca Conti; Tanya Coulter; Lisa A Devlin; J David M Edgar; Saul Faust; Alain Fischer; Marina Garcia-Prat; Lennart Hammarström; Maximilian Heeg; Stephen Jolles; Elif Karakoc-Aydiner; Gerhard Kindle; Ayca Kiykim; Dinakantha Kumararatne; Bodo Grimbacher; Hilary Longhurst; Nizar Mahlaoui; Tomas Milota; Fernando Moreira; Despina Moshous; Anna Mukhina; Olaf Neth; Benedicte Neven; Alexandra Nieters; Peter Olbrich; Ahmet Ozen; Jana Pachlopnik Schmid; Capucine Picard; Seraina Prader; William Rae; Janine Reichenbach; Stephan Rusch; Sinisa Savic; Alessia Scarselli; Raphael Scheible; Anna Sediva; Svetlana O Sharapova; Anna Shcherbina; Mary Slatter; Pere Soler-Palacin; Aurelie Stanislas; Felipe Suarez; Francesca Tucci; Annette Uhlmann; Joris van Montfrans; Klaus Warnatz; Anthony Peter Williams; Phil Wood; Sven Kracker; Alison Mary Condliffe; Stephan Ehl Journal: Front Immunol Date: 2018-03-16 Impact factor: 7.561
Authors: Ivan Angulo; Oscar Vadas; Fabien Garçon; Edward Banham-Hall; Vincent Plagnol; Timothy R Leahy; Helen Baxendale; Tanya Coulter; James Curtis; Changxin Wu; Katherine Blake-Palmer; Olga Perisic; Deborah Smyth; Mailis Maes; Christine Fiddler; Jatinder Juss; Deirdre Cilliers; Gašper Markelj; Anita Chandra; George Farmer; Anna Kielkowska; Jonathan Clark; Sven Kracker; Marianne Debré; Capucine Picard; Isabelle Pellier; Nada Jabado; James A Morris; Gabriela Barcenas-Morales; Alain Fischer; Len Stephens; Phillip Hawkins; Jeffrey C Barrett; Mario Abinun; Menna Clatworthy; Anne Durandy; Rainer Doffinger; Edwin R Chilvers; Andrew J Cant; Dinakantha Kumararatne; Klaus Okkenhaug; Roger L Williams; Alison Condliffe; Sergey Nejentsev Journal: Science Date: 2013-10-17 Impact factor: 47.728